Alnylam Pharmaceuticals (NASDAQ:ALNY) Earns "Buy" Rating from HC Wainwright

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report)'s stock had its "buy" rating restated by HC Wainwright in a report released on Wednesday,Benzinga reports. They presently have a $500.00 price target on the biopharmaceutical company's stock. HC Wainwright's price objective suggests a potential upside of 114.64% from the company's previous close.

Several other equities analysts have also recently issued reports on ALNY. Stifel Nicolaus raised their price target on Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the company a "buy" rating in a report on Monday, March 31st. Chardan Capital reaffirmed a "buy" rating and issued a $300.00 target price on shares of Alnylam Pharmaceuticals in a research note on Friday, March 21st. Bank of America boosted their price target on shares of Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the stock a "buy" rating in a research note on Friday, March 21st. Wells Fargo & Company raised their price objective on shares of Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the company an "equal weight" rating in a research note on Friday, March 21st. Finally, Morgan Stanley upped their target price on shares of Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the company an "equal weight" rating in a research report on Friday, February 14th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty-one have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $316.25.

Remove Ads

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ ALNY traded down $2.79 during trading on Wednesday, reaching $232.95. The company had a trading volume of 1,559,423 shares, compared to its average volume of 847,515. Alnylam Pharmaceuticals has a 52 week low of $141.98 and a 52 week high of $304.39. The business's 50 day moving average price is $259.03 and its 200-day moving average price is $260.14. The stock has a market cap of $30.30 billion, a PE ratio of -107.35 and a beta of 0.30. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.03). Analysts expect that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current year.

Insider Activity

In other news, CMO Pushkal Garg sold 52,592 shares of Alnylam Pharmaceuticals stock in a transaction dated Monday, January 27th. The shares were sold at an average price of $285.00, for a total value of $14,988,720.00. Following the completion of the transaction, the chief marketing officer now owns 11,989 shares of the company's stock, valued at $3,416,865. This trade represents a 81.44 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Phillip A. Sharp sold 11,250 shares of the company's stock in a transaction dated Thursday, January 23rd. The shares were sold at an average price of $275.00, for a total transaction of $3,093,750.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 71,234 shares of company stock valued at $19,958,097. 1.50% of the stock is owned by insiders.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in ALNY. Quantbot Technologies LP boosted its holdings in shares of Alnylam Pharmaceuticals by 1,754.5% during the 3rd quarter. Quantbot Technologies LP now owns 204 shares of the biopharmaceutical company's stock worth $56,000 after buying an additional 193 shares during the period. Captrust Financial Advisors increased its holdings in Alnylam Pharmaceuticals by 34.4% in the 3rd quarter. Captrust Financial Advisors now owns 4,833 shares of the biopharmaceutical company's stock valued at $1,329,000 after buying an additional 1,237 shares during the period. Investment Management Corp of Ontario raised its position in Alnylam Pharmaceuticals by 153.5% during the third quarter. Investment Management Corp of Ontario now owns 7,059 shares of the biopharmaceutical company's stock valued at $1,941,000 after purchasing an additional 4,274 shares in the last quarter. Parkman Healthcare Partners LLC bought a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter worth $7,009,000. Finally, Quantinno Capital Management LP lifted its holdings in shares of Alnylam Pharmaceuticals by 50.3% in the third quarter. Quantinno Capital Management LP now owns 3,366 shares of the biopharmaceutical company's stock worth $926,000 after acquiring an additional 1,126 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company's stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.